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Abstract 
 
Aim: Unwanted pregnancy is an important social issue, not least among teenagers. Emergency 
contraceptives (EMCs) can prevent from unintended pregnancy, if taken quickly after unprotected 
sex. This study’s objective was assessing abortion/birth rates among adult and teenage women in 
Europe before/after an EMC switch to non-prescription status. 
Methods: National authorities were consulted for EMC consumption data and abortion/live birth 
statistics. Rates (n=26 countries) in the year before the switch (= year of reference) were compared 
with rates before/after the change (up to ±15 years). The focus was laid on the European Union 
and further countries closely related to the European Union. 
Results: All countries with available data (n=12) experienced a substantial increase of EMC 
consumption after the switch. On average, abortion rates among women aged 15–49 years were 
83% higher 15 years before (compared with the year of reference) and 14% lower 15 years after 
the switch. Correspondingly, teenage abortion rates were 35% higher 15 years before and 40% 
lower 15 years after the switch. In 2017, no country had higher teen abortion rates than at time of 
the switch. Teen birth rates continued decreasing at almost the same rate after the switch as before. 
Conclusion: An EMC switch to non-prescription status increases EMC use and may contribute 
reducing unwanted pregnancy among teenage girls. 
 
Keywords: Emergency contraceptives, Europe, levonorgestrel, over-the-counter, prescription 
status, ulipristal acetate. 
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Introduction 
For 2008, about 41% of pregnancies 
worldwide were estimated to be unplanned 
(1). Four years later, this proportion was 
stable at 40%, highest in Latin America 
(56%) (2). Unwanted pregnancies are an 
important social issue in Europe as well (rate 
estimated at 45%), and many are likely to end 
in induced abortion (50%) or unplanned birth 
(about 38%). Especially among teenagers, 
the rate of unintended pregnancy is supposed 
to be very high (roughly 80% of all 
pregnancies among American teenagers are 
unwanted) (1). Using long lasting oral 
reversible hormonal contraceptives regularly 
could be an ongoing protection from 
unwanted pregnancy, but this reliable method 
is not used by all fertile women (in 2012, by 
82.5% in Portugal, but only by 33.2% in 
Lithuania) (3). One effective option avoiding 
unintended pregnancy after unprotected sex 
is quickly taking an emergency contraceptive 
(EMC). In Europe, mainly two active 
ingredients are used for emergency 
contraception, levonorgestrel (LNG) and 
ulipristal acetate (UPA), which have to be 
taken within 72 hours (LNG) or 120 hours 
(UPA) after unprotected sex. 
As time is a crucial factor and EMCs are 
considered to have a good safety profile, the 
European Medicines Agency (EMA) 
recommended switching UPA (ellaOne®) 
from prescription-only to non-prescription 
status in November 2014 to speed up access 
to EMCs. The following legally binding 
decision of the European Commission valid 
(in principle) throughout the European Union 
(EU) made UPA available as an over-the-
counter (OTC) drug across the EU (3,4). 
About 20 years ago, when LNG or UPA were 
not (freely) available for emergency 
contraception, pregnancy rates among 
teenagers were higher in many European 
countries compared to 2017, e.g. 55 per 1000 
adolescents aged 15–19 years (England and 
Wales), or 68 per 1000 adolescents aged 15–
19 years in Hungary (5), and most teen 
pregnancies ended in abortions or 
presumably unplanned births. 
One hope linked with facilitated access to 
EMCs was reducing abortion/teen births 
rates. However, also concerns were 
expressed regarding prescription-free 
availability of EMCs, moral worries as well 
as medical fears, e.g. that changes in sexual 
behaviour especially among adolescents 
could also lead to misuse and hence increase 
abortion rates instead of decreasing them (6), 
or that sexually transmitted infections might 
rise again (7,8). 
This study’s objective was to analyse the 
potential impact of an EMC switch to non-
prescription status on unwanted pregnancy. 
This was done by assessing abortion rates 
among women aged 15–49 years and 
abortion and live birth rates among 
adolescents <20 years in Europe since and 
also before the switch of EMCs to non-
prescription status. Within Europe, we 
mainly focused on the European Union (EU) 
and the European Free Trade Association 
(EFTA). A further aim was collecting EMC 
consumption data since their market 
introduction. 
 
Methods 
 
Consumption of EMCs 
EMC consumption was investigated at the 
national medicines authorities (direct contact 
or yearly consumption reports). Another 
source for data on EMC use were drug 
consumption databases and EMC-related 
publications (9,10). 
 
Year of reference 
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Following EMCs with their Anatomical 
Therapeutic Chemical Classification codes 
(ATC) were under research: 
 
1. ATC code G03AD01 (LNG); 
approved first in Eastern Europe in 
1979 and marketed in Western 
Europe since the 1990s. 
2. ATC code G03AD02 (UPA); 
approved in Europe in 2009 and 
recommended by the EMA in 
November 2014 to have non-
prescription status. 
3. ATC  code G03AA07 (levonorgestrel 
+ ethinylestradiol); dedicated 
preparations (brand names 
Tetragynon®, Schering PC4®) 
marketed as prescription-only 
products in several European 
countries (since the 1980s) and first 
EMC with non-prescription status in 
Iceland (in 1998). 
 
The year/month of an EMC switch to non-
prescription status (date one out of the three 
EMCs mentioned above was made available 
without medical prescription for the first 
time) was checked at the national medicines 
authorities (homepage or contact by e-mail). 
Additionally, EMC-related publications were 
screened. The year preceding the switch was 
defined as ‘Year of reference’ for comparing 
development of rates after/before the switch, 
if the switch became operative between 
January and October. For countries where the 
switch came into force in November or 
December, the year of switch was defined as 
‘Year of reference’, as a switch towards the 
end of the year may hardly have had an 
impact on the same year’s abortion statistics. 
The year of switch was defined being the first 
year ‘after’ a switch. Hence, statistics after 
the switch were compared with figures in the 
‘Year of reference’ ended. Correspondingly, 
to take into account long-term trends, also 
rates in the years before the switch were 
compared with rates of the ‘Year of 
reference’ ended. 
 
Analysis of rates 
To obtain statistics on abortions and teen 
births, the homepages of national statistical 
offices were consulted or respective 
authorities were contacted directly (data 
sources available as supplementary material). 
For analysis of induced abortion rates 
(spontaneous abortions were not considered, 
as not mentioned in many abortion statistics) 
among the whole fertile female population, 
the total number of legally induced abortions 
was sought and referred to 1000 women aged 
15–49 years. If stratified data were available, 
induced abortions performed to the countries’ 
residents only were considered. Population 
structures were obtained from national 
statistical offices. Respectively, the number 
of induced abortions and live births (still 
births were excluded, since not available for 
all countries) among adolescents <20 years 
was referred to 1000 women aged 15–19 
years. 
If absolute numbers for abortions/live births 
were not available, rates were adopted as 
reported by the countries’ authorities. 
Generally, abortion and live birth rates for 
women aged 15–19 years presented in this 
study mostly include the figures for girls <15 
years, as this is mainly the method how 
authorities report the rates for this age group. 
However, abortion/birth figures for girls <15 
years are almost negligible for the calculation 
of teenage abortion/birth rates. 
Abortion statistics for residents from Ireland 
and Northern Ireland were extracted from the 
annual abortion reports of the United 
Kingdom, since Ireland and Northern Ireland 
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have very restrictive abortion laws and only 
few abortions were performed in Ireland and 
Northern Ireland. 
Rates for countries (e.g. England and Wales, 
the Netherlands, Sweden) generally reporting 
rates among women aged 15–44 years 
(instead of 15–49 years) were recalculated 
for the 15 to 49-year-old female population. 
For some years, figures on abortions or live 
births were not available from the national 
authorities. Therefore, rates were extracted 
from graphs provided by national 
health/statistical authorities or calculated 
based on figures from the historical Johnston 
archive (11), the World Health Organization 
(12), Eurostat (13), or the World Bank (14). 
Data were collected up to the year 2017. 
 
Results 
 
History of EMC accessibility 
Exactly 26 countries were included in this 
comparative study (23 EU countries, 3 EFTA 
countries). Iceland (1998) and France (1999) 
were the first countries making EMCs 
available without medical prescription. 
According to the Icelandic medicines agency, 
the first EMC available (Tetragynon®) was 
classified as OTC medicine immediately 
after receiving marketing authorization in 
June 1998, as well as LNG, which was freely 
available since January 2003. Among the last 
European countries changing at least one 
EMC (UPA or LNG) to OTC status were 
Germany, Italy, and Croatia (all in 2015). 
Hungary decided keeping the prescription-
only status for all EMCs, Poland switched 
UPA to OTC status in April 2015, but the 
new Polish government abolished the 
decision and re-switched UPA to 
prescription-only status again in July 2017 
(LNG never received OTC status in Poland). 
The most recent European countries making 
EMCs accessible without medical 
prescription were Malta (December 2016) 
and Andorra (June 2018). 
In Gibraltar, a self-governing British 
Overseas Territory, EMCs were switched to 
OTC status in August 2017 only, about 8 
years after the switch in the neighbouring 
country Spain, and more than 16 years later 
than in the United Kingdom itself. 
 
Rates after the switch 
In the year before the switch, total abortion 
rates ranged between 3.2 (Croatia) and 31.5 
(Estonia) abortions per 1000 women aged 
15–49 years. The mean for the 26 included 
countries was 11.8. Exactly 19 countries 
experienced a reduction of abortion rates 
since the switch. The sharpest decline was 
observed in Latvia (-63% within 15 years). In 
7 countries, abortion rates among the total 
female population were slightly higher in 
2017 (or in the year with most recent 
available figure) compared with the year of 
reference (Table 1). 
The development of abortion rates among 
adolescents aged 15–19 years revealed a 
relatively uniform picture (Table 1). In all 
countries except Belgium and Greece (for 
which most recent figures were available for 
2011 and 2012 only) abortion rates fell. The 
biggest reductions since the switch were 
visible in Latvia (-73%) and Norway (-67%). 
On average, abortion rates dropped from 12.0 
at time of the switch to 6.9 abortions/1000 
adolescents aged 15–19 years in 2017. 
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Table 1. Induced abortion and live birth rates at time of the OTC switch compared  
with rates in 2017 
 
   Rates in the year of referencea Rates in 2017a 
Country Switch Reference 
Abortions 
15-49 
Abortions 
15-19 
Births 
15-19 
Abortions 
15-49 
Abortions 
15-19 
Births 
15-19 
Belgium Apr 01 2000 5.6 6.9 10.7 7.8* 8.4* 5.8 
Bulgaria Jan 06 2005 22.4 15.6 40.4 16.0 14.3 39.7 
Croatia Apr 15 2014 3.2 1.8 10.3 2.7 1.5 9.3 
Czech Republic Nov 11 2011 9.6 7.1 11.3 8.2 5.6 11.9 
Denmark Jun 01 2000 12.5 14.2 7.9 12.1*** 11.3*** 2.8 
Estonia Sep 03 2002 31.5 28.9 23.0 13.9 10.8 10.1 
Finland Jan 02 2001 8.9 15.5 10.7 8.2 7.6 4.9 
Franceb May 99 1998 13.4 13.2 7.1 14.4 10.4 4.7 
Germany Mar 15 2014 5.6 4.4 6.1 5.8 4.0 6.3 
Greece Jun 05 2004 6.0 2.1 10.8 6.8** 2.4** 9.0 
Iceland Jun 98 1997 13.6 20.6 24.3 13.3 12.6 6.0 
Ireland Feb 11 2010 3.7 3.2 14.4 2.6 1.4 6.9 
Italy Apr 15 2014 7.0 5.4 5.6 6.2 4.3 4.3 
Latvia May 03 2002 25.1 17.0 21.5 9.2 4.6 15.0 
Lithuania Jul 08 2007 11.7 7.3 19.5 6.9 3.2 12.2 
Netherlands Jan 05 2004 7.4 8.2 4.6 7.2 5.3 2.0 
Norway Jul 00 1999 13.4 19.0 11.7 10.6 6.3 3.0 
Romania Nov 06 2006 28.3 23.1 40.1 12.4 10.2 38.5 
Slovak Republic Apr 04 2003 9.8 6.6 20.8 5.8 4.3 27.3 
Slovenia Mar 11 2010 9.0 6.7 4.9 8.1 4.0 4.0 
Spain Sep 09 2008 9.7 12.7 13.2 8.7 8.8 7.2 
Sweden Apr 01 2000 15.6 21.1 5.0 16.8 13.0 3.1 
Switzerland 
(Cantone 
Berne)c 
Oct 02 2001 5.2 4.9 3.4 5.0 3.2 2.1 
UK (England & 
Wales) 
Jan 01 2000 14.1 23.7 29.3 14.4 14.7 12.7 
UK (Scotland) Jan 01 2000 9.6 18.4 29.3 9.9 12.9 13.0 
UK (Northern 
Ireland) 
Jan 01 2000 3.7 4.8 25.6 2.2 2.1 12.4 
Mean   11.8 12.0 15.8 8.9 6.9 10.5 
aRates are displayed per 1000 women of the respective age group (figures for girls <15 years are normally included) 
bFrance métropolitaine (=France without Guadeloupe, Martinique, Guyane, La Réunion, Mayotte)    
cNo long-term abortion data available for Switzerland as a whole       
Rates in bold letters are higher compared with rates in the year of reference      
* 2011 figures         
** 2012 figures         
***2015 figures    
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Live birth rates among women aged 15–19 
years fell in most countries. Only the Czech 
Republic and Germany had slightly higher 
rates in 2017 compared with the year of 
reference. However, the Slovak Republic had 
clearly higher birth rates after the switch and 
was the only country in this study were the 
sum of teenage abortion and live birth rates 
was higher in 2017 compared to the year of 
reference. 
Further abortion and live birth rates for some 
European countries with incomplete statistics 
are displayed in Table 2. 
 
 
Table 2. Induced abortion and live birth rates for further European countries 
 
   Rates in the year of referencea Rates in 2017a 
Country Switch Reference 
Abortions 
15-49 
Abortions 
15-19 
Births 
15-19 
Abortions 
15-49 
Abortions 
15-19 
Births 
15-19 
Andorra Jun 18 2017 na na 3.4 na na 3.4 
Austria Dec 09 2009 no stat no stat 10.4 no stat no stat 6.8 
Cyprus ? --- no stat no stat --- no stat no stat 6.6 
Hungary Still Rx --- na na na 12.6 16.1 23.2 
Luxembourg May 05 2004 no stat no stat 10.9 no stat no stat 5.2 
Malta Dec 16 2016 na na 13.6 na na 12.5 
Polandb Apr 15 2014 na na 13.4 na na 11.1 
Portugal Oct 00 1999 na na 21.1 6.7 5.5 8.0 
Rx=prescription-only          
na=not applicable (abortion illegal or EMCs available with prescription only)      
no stat=no official data available          
?=EMCs have OTC status, but date of switch not determinable 
aRates are displayed per 1000 women of the respective age group (figures for girls <15 years are normally included)  
bEMCs were re-switched to prescription-only status in July 2017       
   
 
Long-term analysis of rates 
Fifteen years before the switch, the average 
abortion rates were 26.9 per 1000 women 
aged 15–49 years (data available for n=25 
countries) and 15.2 per 1000 girls aged 15–
19 years (data available for n=20 countries), 
ranging from 4.4 (Northern Ireland) to 153.8 
(Romania) for all age groups and from 1.6 
(Greece) to 55.0 (Romania) for teenagers. 
Live birth rates (mean=24.4; data available 
for n=26 countries) were lowest in 
Switzerland (3.0) and highest in Bulgaria 
(69.9). 
In the mean, abortion rates among women 
aged 15–49 years were 83% higher 15 years 
before the switch in comparison with the year 
of reference, whereas 15 years after the 
switch, rates were 14% lower compared with 
the year of reference (Figure 1). The 
corresponding percentages for abortions 
among teenagers were +35% (15 years before 
switch) and -40% (15 years after the switch). 
Hence, the falling trend for abortions among 
teenagers was visible already before the 
EMC switch, but the mean decline was 
stronger after the switch. In contrast, for all 
age groups the trend towards lower abortion 
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rates was almost stopped after the switch 
(also when considering that the slight decline 
after the switch is mostly attributable to the 
decline among adolescents, which are 
included in the figures for the total age 
groups). 
On average, live birth rates declined at almost 
the same rate after the switch as they did 
already before the EMC change to OTC 
status. 
 
Figure 1. Long-term analysis of abortion/live birth rates for n=26 European countries 15 
years before and after the year of reference.* 
 
 
*For the calculation of the mean relative change  (rate in the year concerned/rate in year of reference), each country contributes the 
relative change according to availability of data (e.g. Denmark for all years from -15 to +15, Ireland from -15 years to +7 years, 
etc.). 
 
In most countries from Eastern Europe, 
abortion rates declined extremely after the 
fall of the Berlin Wall in 1989, which might 
be explained by the fact that regular 
contraceptives were used less compared with 
Western Europe. Hence, abortion might have 
been regarded being a common option for 
family planning. 
For eight countries from Western Europe 
only (Finland, Denmark, Iceland, Norway, 
Sweden, Switzerland, United Kingdom 
(England & Wales), United Kingdom 
(Scotland)), a full history of 15 years before 
and after the EMC switch is available. These 
countries (Figure 2) may therefore provide a 
picture which is biased less by social turmoil 
as it might have been if including also data 
from Eastern Europe (Figure 1). Moreover, 
almost all dispensing pharmacists from these 
eight countries may have respected non-
prescription rules before the switch, which 
may possibly not be the case if viewing at all 
26 included countries. 
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Figure 2. Long-term analysis of abortion/live birth rates 15 years before and after the year 
of reference for eight countries with a complete ±15 year-history before/after the EMC 
switch.* 
 
 
*The eight included countries are Finland, Denmark, Iceland, Norway, Sweden, Switzerland, United Kingdom (England & 
Wales), United Kingdom (Scotland). 
 
EMC sales figures 
For 12 countries, precise consumption 
numbers or sufficiently reliable estimations 
were available (Figure 3). Almost all 
countries showed a quick and strong increase 
of sales after the switch and reached an 
almost stable consumption peak after 8–10 
years, seven countries evening out at about 
80–100 used EMCs per 1000 women aged 
15–49 years per year. Norway, showing the 
biggest increase, is observing a reduction of 
EMC use since reaching the peak ten years 
after the switch, now also approaching a level 
of 100 EMCs per 1000 women aged 15–49 
years. Across the included countries, a direct 
linear correlation of EMC consumption and 
abortion rates is, however, not visible, as e.g. 
France and Finland have now similar per 
capita EMC consumptions, but different 
abortion rates. The results (Figure 3) are 
approximately in line with corresponding 
results from a study providing estimations of 
EMC consumption in 2013 for almost all EU 
countries (15). Nevertheless, several 
countries with the lowest per capita 
consumption of EMCs in 2013 are currently 
among the EU countries with the highest 
teenage abortion and/or live birth rates 
(Romania, Bulgaria, Hungary, Slovakia, 
England & Wales, Czech Republic, Poland). 
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Figure 3. EMC consumption over time (figures include ATC codes G03AD01, G03AD02 
and G03AA07).* 
 
 
*For Scotland, the consumption may be underestimated between 2001 (year of switch) and 2008 (introduction of free-of-costs 
program) as figures for EMCs sold without prescription are not available and hence are not included in data provided by the 
National Health Service in Figure 3. 
 
 
For further countries with no long-term data 
on EMC consumption, there have been 
reports of markedly higher EMC use after the 
switch, e.g. Switzerland, Portugal, Spain (16-
18). 
 
Discussion 
Emergency contraception is a highly 
controversially discussed topic, to which 
various societal institutions such as 
medical/pharmaceutical societies, the 
churches, or feminist organizations 
contribute their opinion, which may 
sometimes be based more on personal beliefs 
or interests rather than on crude facts. The 
issue of barrier-free access to EMCs 
deserves, however, a sober analysis, 
evaluating its potential risks and benefits, as 
discussed for LNG in a 2003 publication 
(19). 
The efficacy of EMCs containing LNG or 
UPA has been proven sufficiently by several 
studies (20,21). Similarly, the EMA 
estimated that for women taking UPA within 
five days after unprotected sex, it would be 
able to prevent about three-fifths of 
pregnancies. Based on the positive risk-
benefits ratio, the EMA recommended UPA 
to be changed to non-prescription status 
throughout Europe (22). 
In contrast to some concerns expressed 
before, facilitated access to EMCs did not 
increase teen abortion rates in general, e.g., 
due to a change of sexual behavior, incorrect 
or excessive use of EMCs instead of ongoing 
hormonal contraception (23). No country 
(except Belgium and Greece, where latest 
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available figures are from 2011/2012 and 
may have fallen since then) showed long-
term trends towards higher abortion rates 
among teenagers after the switch, and in only 
seven countries total abortion rates were 
slightly higher in 2017 than at time of the 
switch. 
Interestingly, in Andorra, having very 
restrictive abortion laws, live birth rates were 
almost stable from 2000 to 2008 for younger 
and older women as well. Since 2009, rates 
began falling strongly until 2017 for the two 
youngest age groups (-60% for teenagers; -
63% for women aged 20–24 years), while 
live birth rate for women aged 25–49 years 
fell by only 20%. Two EMC-related events 
may explain the drop especially among 
young girls: firstly, EMCs were available in 
Andorra at least with a medical prescription 
since 2008 (switch to OTC in 2018 only), and 
secondly, EMCs received OTC-status in the 
bordering state of Spain in 2009, easily 
accessible in case of need for women residing 
in Andorra. 
A 2016 study found a direct correlation 
within Germany of higher EMC use with 
lower abortion rates. German regions with 
highest use (Bavaria, Baden-Württemberg) 
showed the lowest abortion rates, those with 
lowest use had the highest abortion rates 
(Saxony-Anhalt, Mecklenburg-
Vorpommern) (24). On the other hand, the 
question arises whether in countries with a 
substantial growth of EMCs sales after the 
switch abortion/teen birth rates should not 
have declined stronger and faster after the 
switch than observed in reality (e.g. France). 
Possibly, country-specific social factors have 
also great weight, and perceptible reductions 
of abortion rates should not be expected 
quickly, anyway, as it takes roughly 8–10 
years on average until EMC consumption 
reaches an almost stable maximum. 
Additionally, it may also take several years 
until most girls have learned using EMCs 
correctly (quick administration; taking a 
second dose in case of emesis within 3 hours 
after the first dose; respecting interactions 
with other medicines; etc.). 
With concern to EMCs’ action of 
mechanism, the WHO asserted clearly that 
LNG and UPA have no abortifacient effects 
(25). However, this debate has not been fully 
settled yet, and some authors state that 
EMCs’ actions of mechanism (especially 
with regard to UPA) might potentially be 
interpreted as being abortifacient (26-28). 
Nevertheless, even if EMCs should have 
abortifacient effects, the question rises, how 
many of the women not taking an EMC 
(because of restricted access) after 
unprotected sex would finally anyway seek 
abortion service if getting pregnant 
unintentionally. Hence, it could be discussed 
if a hypothetical early-stage abortion would 
not be preferable to having a real abortion at 
a later stage of pregnancy, which of course is 
a serious and stressing decision. 
Unwanted pregnancy represents an economic 
burden for society as well, as shown for 
Norway (for teenagers, direct and indirect 
costs estimated at €1573 per unwanted 
pregnancy) and the UK (direct health care 
costs estimated at £1663 per unwanted 
pregnancy) (29,30). Thus, it may be worth it 
also from an economic point of view 
assessing whether EMCs should be covered 
by social security (at least for teenagers), 
although an increase of EMC consumption 
after a switch, of course a welcome business 
for the producing pharmaceutical companies, 
may be a challenge for those social security 
systems fully covering EMCs (31). However, 
some studies/figures showed that barrier-free 
access to EMCs seems sometimes to be more 
important rather than full coverage (32,33). 
  
Italia S, Schröder-Bäck P, Brand H. Switching emergency contraceptives to non-prescription status 
and unwanted pregnancy among adult and teenage women: A long-term European comparative study 
(Original research). SEEJPH 2020, posted: 17 January 2020. DOI: 10.4119/seejph-3277 
 
 
 
P a g e  12 | 16 
 
It is, finally, an ironic twist of fate, that the 
very country (Hungary), where modern 
LNG-containing EMCs had been developed 
and approved first in 1979 is now one of the 
very few European countries keeping the 
prescription-only status for LNG and UPA 
(34,35). Remarkably, in contrast to most of 
the other countries, abortion rates among 
Hungarian teenagers fell only slightly since 
2001 (16.1 in 2017 vs. 19.7 in 2001), and teen 
live births rates are almost on the same high 
level (23.2 in 2017 vs. 22.0 in 2001) as one 
and a half decades ago. Today, both teen 
abortion and live birth rates in Hungary are 
among the highest in Europe. 
 
Limitations 
For this study, recent/historical abortion 
statistics for most EU and EFTA countries 
were collected from national statistical 
offices or health authorities, which are 
supposed to provide the best possible 
national data on abortion and birth statistics. 
To our knowledge, this is the first study 
comparing on European level the 
development of abortion rates with respect to 
the year EMCs were made available without 
medical prescription. However, no data were 
available for the EFTA country Liechtenstein 
and for two micro-states closely related to the 
EU (San Marino, Monaco). 
The quality and methods of data collection 
may vary across the European countries as 
well as legal definitions of ‘abortion’ or 
differences between officially reported 
numbers of legally induced abortions and 
estimated numbers of induced abortions 
actually performed (e.g. Greece) (36). 
Several aspects may have interfered with the 
use of EMCs and development of abortion 
rates over time. However, according to age-
stratified consumption data from Denmark 
and Sweden (precise data from other 
countries are scarce), use of conventional 
hormonal contraceptives (which may also 
have changed over time) was not directly 
linked to the development of abortion/birth 
rates during the respective observation 
periods. 
No reliable information is available about 
how the legal status of pharmaceuticals is 
respected by pharmacies in the included 
countries. In some countries, prescription-
only status may exist pro forma only (37), 
thus self-medicated EMCs may have 
influenced abortion/live birth rates already 
before the formal switch to over-the-counter 
status. 
Finally, the exact levels of awareness about 
and correct use of EMCs were not available, 
and it is likely that time to reach high levels 
of awareness about OTC availability of 
EMCs and their correct use differ between 
countries. 
 
Conclusions 
This study cannot provide evidence of a 
causal link between an EMC switch and 
subsequent changes in abortion/live birth 
rates. However, pooled data, timely 
correlation of drops in abortion/live birth 
rates with EMC switch and the increase of 
EMC use after the switch suggest that over-
the-counter availability of EMCs contributes 
reducing unwanted pregnancy especially 
among teenagers. Further studies are 
necessary to explain why in many countries 
the reduction of abortion rates was limited 
mainly to younger age groups (according to 
Danish data, per capita use of EMCs is 
highest among teenagers, thus possibly older 
women use generally EMCs less in other 
countries, too). Also, the question should be 
addressed why in some countries the decline 
of abortion rate was visible several years after 
the EMC switch only, despite of an 
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immediate and substantial rise in EMC 
consumption after the change. Weighing the 
pros and cons, it seems that in sum, the 
benefits of OTC access to EMCs may prevail. 
Additional measures such as free-of-cost 
dispensing of EMCs to minors or intensive 
information campaigns may support 
achieving lower abortion rates, if the switch 
to non-prescription status proves being not 
sufficient. Reasonable self-medication, 
however, requires safe and affordable drugs, 
access to high-quality advice about EMCs 
(e.g. in pharmacies) and/or well informed 
people. 
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